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Pannexin 1 channels regulate leukocyte emigration
through the venous endothelium during acute
inflammation
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Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by a
plethora of signalling processes influencing cell-to-cell interactions between the vascular
endothelial cells (ECs) in post-capillary venules and circulating leukocytes. Recently,
ATP-sensitive P2Y purinergic receptors have emerged as downstream regulators of EC
activation in vascular inflammation. However, the mechanism(s) regulating cellular ATP
release in this response remains elusive. Here we report that the ATP-release channel
Pannexin1 (Panx1) opens downstream of EC activation by TNF-a. This process
involves activation of type-1 TNF receptors, recruitment of Src family kinases (SFK) and
SFK-dependent phosphorylation of Panx1. Using an inducible, EC-specific Panx1 knockout
mouse line, we report a previously unidentified role for Panx1 channels in promoting leukocyte
adhesion and emigration through the venous wall during acute systemic inflammation,
placing Panx1 channels at the centre of cytokine crosstalk with purinergic signalling in the
endothelium.
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A
cute vascular inflammation is a central physiological host
defence and repair system that encompasses the innate
trafficking and targeting of circulating inflammatory cells
(primarily neutrophils) to local sites of tissue injury or infection
(see ref. 1). The vascular inflammatory response is essential for
the homeostatic balance of cellular turnover and proper clearance
of potentially hazardous pathogens and necrotic cell debris that
accompanies the resolution of traumas.
As our understanding of the acute inflammatory response has
expanded, a prominent role for extracellular signalling by
adenosine triphosphate (ATP) and its metabolic breakdown
products has emerged. The extracellular accumulation of the
purine nucleotides ATP, adenosine diphosphate (ADP) or
adenosine can trigger intracellular signalling cascades through
the activation of plasma membrane purinergic receptors2.
Recently, using pharmacological inhibitors and genetically
modified mice, Zerr et al. identified a pivotal role for vascular
purinergic receptor P2Y1 in signalling the pro-inflammatory
effects of tumour necrosis factor-alpha (TNF-a) and
interleukin-1b (IL-1b). When challenged with TNF-a and
IL-1b, mice lacking P2Y1 receptors displayed a significant
reduction in leukocyte recruitment3. Furthermore, inhibiting
P2Y1 function in isolated murine endothelial cells (ECs)
prevented the TNF-a-dependent upregulation of adhesion
molecules including P-selectin, VCAM1 and ICAM1 (ref. 3).
In a separate study, the endothelial P2Y6 receptor was shown to
control TNF-a-induced inflammatory gene transcription, where
pharmacological inhibition of P2Y6 receptors potently reduced
NFkB activity and downstream transcription of the pro-
inflammatory cytokine IL-8 and VCAM1 (ref. 4). Moreover,
mice genetically lacking P2Y6 had reduced VCAM1 expression
and preserved EC barrier integrity when challenged with
lipopolysaccharide, a bacterial toxin that increases plasma TNF-
a levels4. As extracellular ATP concentrations increase, ecto-
enzymes at the EC:leukocyte surface actively degrade the purine
to ADP, adenosine monophosphate (AMP) and adenosine.
The ectonucleoside triphosphate diphosphohydrolase CD39
(ecto-apyrase) degrades ATP and ADP to AMP, while
50-nucleotidase (CD73) functions to remove the terminal
phosphate from AMP yielding adenosine. Consistent with
reports implicating purinergic receptors in the vascular
inflammatory response, these ecto-enzymes have also been
reported to modulate leukocyte recruitment in a number of
models of inflammation. For example, mice deficient in CD39
(ecto-apyrase) exhibit enhanced leukocyte targeting to sites of
inflammation in the liver and lung5–7. In addition, mice lacking
CD73 have exacerbated leukocyte–EC interactions during
inflammatory stress, and multiple lines of evidence now
indicate adenosine as an anti-inflammatory molecule8,9. On the
basis of these observations, purinergic mechanisms play an
important role in regulating vascular inflammation and the
relative abundance of extracellular ATP and adenosine balances
pro- and anti-inflammatory signalling processes; however, the
precise mechanism(s) that mediate/regulate ATP release during
this physiological response remains unknown.
The pannexin (Panx) family of channel-forming proteins are
expressed in the vasculature10–13. Panxs exist in three isoforms
(Panx1, Panx2 and Panx3), which are differentially expressed
throughout the body. Panx1, the most highly expressed member
in the vascular wall, is thought to form hexameric channels
permeable to ions and metabolites up to B1 kDa in size,
including ATP14,15. To date, the major function of these channels
has been ascribed to the release of ATP and as a result, Panx1
channels provide a strong candidate for vascular ATP release
during inflammation. Outside of vascular cells, Panx1 channel
function has been implicated in several inflammatory processes16.
In particular, Panx1 channels promote activation of the
inflammasome in macrophages, neurons and astrocytes17,18,
regulate chemotaxis of phagocytes during apoptosis19, promote
T-cell activation20, induce neuronal death during enteric colitis21
and regulate lung inflammation22. Collectively, these studies
indicate increased Panx1 channel function during inflammatory
stress and provide a framework for understanding the link
between cytokine and purinergic signalling pathways in a number
of organ systems. The focus of this work is to define the
mechanism of ATP release from vascular ECs during
inflammatory activation, and address whether Panx1 channels
provide the conduit for nucleotide release to promote interactions
between circulating inflammatory cells and the endothelium,
which has been previously undefined.
Here we show that EC Panx1 channels release ATP in response
to activation by the pro-inflammatory cytokine TNF-a, which
requires activation of type-1 TNF receptors and downstream
signalling through Src family kinases (SFK). The release of ATP
promotes upregulation of Panx1 phosphorylation at Y198 and
vascular cell adhesion molecule 1 (VCAM1), which regulates
leukocyte adhesion and diapedisis through the post-capillary
venule wall.
Results
TNF-a induces ATP release from venous ECs. To test whether
post-capillary ECs provide a releasable pool of ATP in response to
activation by inflammatory mediators, we assessed ATP release in
response to activation by the pro-inflammatory cytokine TNF-a.
First, we developed an ex vivo vascular perfusion assay to
selectively deliver TNF-a to the endothelium of intact murine
arterioles and venules. Following microdissection of paired
second-order mesenteric arterioles and venules, vessels were
cannulated on glass micropipettes mounted in a temperature-
controlled bath allowing access to the lumen and direct perfusion
to a collection reservoir for sample acquisition (Fig. 1a). Perfusion
of recombinant murine TNF-a through the lumen of mesenteric
venules produced a time- and dose-dependent increase in ATP
accumulation in the perfusate as assessed by luciferin:luciferase-
based bioluminescence (Fig. 1b). Perfusion of TNF-a did not
induce cell death evidenced by a lack of lactate dehydrogenase
(LDH) accumulation in perfusates (Fig. 1c). Interestingly, this
response was absent in paired mesenteric arterioles (Fig. 1d). The
endothelium primarily senses soluble TNF-a via TNF receptor
type 1 (TNFR1); therefore, we used a peptide antagonist of this
receptor (WP9QY) to examine whether ATP release occurs via a
TNFR1-dependent mechanism. Lumenal perfusion of WP9QY
prior to EC activation with TNF-a significantly ablated the
TNF-a-induced ATP release from intact venous endothelium,
indicating a direct involvement of this receptor isoform (Fig. 1e).
To further dissect the molecular mechanisms controlling ATP
release in this response, we performed in vitro ATP release assays
on two independent primary venous EC types derived from
human umbilical vein (HUVEC) and human saphenous vein
(HSaVEC) cells. Following activation with recombinant human
TNF-a, we observed a significant increase in ATP accumulation
in the supernatant surrounding both HUVEC and HSaVEC
monolayers (Fig. 1f,g). Similar to isolated venules, TNF-a
stimulation did not activate caspase-dependent cell death
pathways in cultured cells, as evidenced by lack of inhibition in
ATP release with the pan-caspase inhibitor Q-VD-OPh
(Supplementary Fig. 1). Consistent with the intact mesenteric
venous endothelium, ATP release from cultured venous ECs
increased in a dose- and time-dependent manner with maximal
accumulation of extracellular ATP achieved following EC
activation with 10 ngml 1 TNF-a for B10min. Similar to
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ex vivo analyses, two primary arterial EC types, human aortic
(HAoEC) and human coronary artery (HCoAEC), failed to
release ATP upon TNF-a stimulation (Fig. 1f,g). This difference
in response was not due to differential expression of TNFR1
in the isolated arteriole:venule pairs or the primary ECs
(Supplementary Fig. 2a,b). Moreover, blockade of TNFR1 sig-
nalling with WP9QY reduced the ATP release in response to
increasing doses of TNF-a on cultured venous ECs, consistent
with the ex vivo observations (Fig. 1h; Supplementary Fig. 4a).
Next, we aimed to examine the ability of another prominent
pro-inflammatory cytokine IL-1b to induce ATP from venous
ECs. In contrast to TNF-a, IL-1b failed to promote ATP release
from HUVEC and HSaVEC monolayers (Supplementary
Fig. 3a,b). Co-administration of IL-1b with TNF-a did not
significantly alter the degree of ATP release as compared with
TNF-a stimulation alone, suggesting a mechanism specific to
TNFR1 activation (Supplementary Fig. 3c,d). Taken together,
these results provide new evidence for the ability of TNF-a to
induce ATP release from venous ECs through a signalling process
specific to activation of the membrane receptor TNFR1.
Panx1 controls ATP release by venous ECs. We next sought to
identify the specific pathway regulating ATP release activated by
TNF-a. Multiple regulated ATP release pathways have been
reported in the vasculature, including prominent roles for vesi-
cular and channel-dependent ATP release primarily involving
connexins (Cx) hemichannels and Panx1 channels23 (Panx1 is the
predominant isoform expressed in the systemic vasculature10;
Supplementary Fig. 2c). These two protein families share a similar
membrane topology, and distinguishing connexin hemichannels
from pannexin channels in cellular ATP release has often proved
cumbersome due to overlapping expression profiles in a number
of cell types and the lack of specific pharmacological inhibitors24.
Therefore, we took a multifaceted approach to dissect the
TNF-a-mediated ATP release pathway. Initially, to discriminate
between the involvement of connexin hemichannels and Panx1
channels in this process, we used a biochemical method to
selectively deplete connexins from the EC plasma membrane
without affecting the localization of Panx1. Taking into
account the relative half-life of each channel at the cell surface
(Cx hemichannels: 1–5 h (ref. 25), Panx1 channels:46 h (ref. 26)),
treatment of HUVEC and HSaVEC with the vesicular exocytosis
inhibitor brefeldin A (BFA; 5mgml 1) prevented trafficking of
newly synthesized Cx hemichannels and Panx1 channels to the
cell surface while preserving internalization of older channels.
Due to the relatively short half-life of Cx43 hemichannels (the
major Cx isoform implicated in ATP release), 5 h treatment with
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Figure 1 | Venous endothelial cells release ATP when activated by TNF-a. (a) Schematic of ex vivo vascular perfusion assay. (b) TNF-a-induced ATP
release from isolated murine mesenteric venules. TNF-a promoted a time- and dose-dependent increase in ATP release from the endothelium. *Po0.05,
**Po0.01 and ***Po0.001 as compared with vehicle-perfused controls (n¼4). (c) LDH release from isolated venules perfused with TNF-a or lysis buffer.
(d) ATP release from isolated mesenteric venules (V) and paired arterioles (A) in response to TNF-a (50 ngml 1) perfusion. ***Po0.001 versus venule
(n¼4). (e) Time course of ATP release from mesenteric venules following inhibition of TNFR1 with WP9QY (10mM). *Po0.05 and **Po0.01 versus the
corresponding vehicle time point (n¼4). (f) Dose response of primary human venous (HUVEC and HSaVEC) and arterial (HAoEC and HCoAEC) ECs to
TNF-a. HUVEC, human umbilical vein endothelial cell; HSaVEC, human saphenous vein endothelial cell; HAoEC, human aortic endothelial cell; HCoAEC,
human coronary artery endothelial cell. *Po0.01 compared with unstimulated cells and #Po0.005 as compared with venous cells (n¼ 5). (g) Time course
of ATP release from cultured arterial and venous ECs. Cells were stimulated with 10 ngml 1 TNF-a. (h) Dose response of HUVEC to TNF-a following
inhibition of TNFR1 with WP9QY (10 mM). *Po0.05 as compared with vehicle control (n¼ 5). All data are presented as mean±s.e.m. (error bars).
Statistical analyses were performed using one-way analysis of variance.
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BFA decreased the expression of Cx43 at the EC surface without
significantly altering the expression of Panx1 in both HUVEC
(Fig. 2a) and HSaVEC (Supplementary Fig. 4b). Importantly,
under these experimental conditions, the ability of TNF-a to
induce ATP release was unaffected, suggesting that Panx1 channels
may be more likely to mediate ATP release in response to the
inflammatory cytokine (Fig. 2b; Supplementary Fig. 4c).
To more directly interrogate the contribution of Panx1
channels to ATP release from venous ECs, we used two
independent Panx1 pharmacological antagonists to block channel
function, carbenoxolone (CBX) and the Panx1 inhibitory peptide
10panx1. In HUVEC, Panx1 channel blockade with CBX (50 mM)
or 10panx1 (200 mM) significantly reduced TNF-a-mediated
ATP release by 86.4 and 70.9%, respectively (Fig. 2c,d). Similar
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Figure 2 | Pannexin 1 channels mediate TNF-a-induced ATP release from venous ECs. (a) Representative western blot of HUVEC treated with brefeldin
A (BFA; 5 h) and subsequent cell surface biotinylation of membrane proteins. Plasma membrane localization of Panx1 and Cx43 were assessed
using isoform-specific antibodies to each protein. (b) ATP release from BFA-treated HUVEC in response to TNF-a (10 ngml 1) treatment for 30min.
(c,d) Time course of ATP release from HUVEC following inhibition of Panx1 channels with carbenoxolone (CBX: 50mM) (c) and the Panx1 blocking peptide
10panx1 (200mM) (d). *Po0.05 as compared with vehicle control (n¼ 5). (e) Summary data of pharmacological inhibitors assessed for inhibition of
TNF-a-induced ATP release from HUVEC. BFA (30min): inhibition of vesicular release, Ruthenium red (RuR): antagonist of CALHM1 channels. Lanthanum
(La3þ ): Cx hemichannel antagonist. *Po0.05 as compared with BFA, RuR and La3þ (n¼ 5). (f) Representative western blots of siRNA knockdown of
Panx1 and Cx43 in HUVEC. ***Po0.005 and ****Po0.001 versus control (n¼ 3). (g) ATP release from Panx1 and Cx43 siRNA-treated HUVEC from f in
response to TNF-a (10 ngml 1). ***Po0.005 versus control (n¼ 3). (h) Schematic representing the generation of an inducible, EC-specific Panx1 knockout
mouse (VECadERT2þ/Panx1fl/fl). (i) En face immunofluorescence micrographs of Panx1 (red) expression of endothelium from VECadERT2þ/Panx1fl/fl mice
injected with tamoxifen (Tam) or its vehicle peanut oil (PO) for 10 consecutive days. Nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI) (blue).
Scale bar, 10mm. (j) Immuno-scanning electron micrographs (iSEM) of isolated mesenteric venules from VECadERT2þ/Panx1fl/fl mice. Veins were
immunolabelled for Panx1 (pseudo-coloured magenta) using an antibody against the extracellular region of the channel. Right panels are zoomed images of
the left panels. Scale bar, 10mm; enlarged boxes are 5 5 mm. (k) TNF-a-induced ATP release from isolated mesenteric venules from VECadERT2þ/Panx1fl/fl
mice injected with Tam or PO for 10 days. Venules were perfused with 50 ngml 1 TNF-a or vehicle. *Po0.05 as compared with vehicle-perfused controls
and #Po0.05 as compared with POþTNF-a (n¼4). All data are presented as mean±s.e.m. (error bars). Statistical analyses were performed using
one-way analysis of variance. NS, not significant.
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inhibition was observed in HSaVECs (CBX: 69.7%, 10panx1:
75.2%; Supplementary Fig. 4d). Furthermore, blockade of Cx
hemichannels with lanthanum (La3þ ;100 mM) failed to reduce
ATP release (Fig. 2e). Additional pharmacological interrogation
ruled out the involvement of vesicular mechanisms (blocked with
BFA) and calcium homeostasis modulator 1 (CALHM1) channels
(inhibited with ruthenium red27), which have recently been
identified as potential ATP release channels (Fig. 2e;
Supplementary Fig. 4d). Moreover, employing RNA
interference, selective knockdown of Panx1 in HUVEC and
HSaVEC with short interfering RNA (siRNA) duplexes targeting
the PANX1 gene affirmed a central role for these channels in
TNF-a-induced ATP release, with no observed inhibition upon
Cx hemichannel depletion with Cx43 siRNA. Knockdown
efficiency was B65 and B75% in HUVEC (Fig. 2f) and
HSaVEC (Supplementary Fig. 4e), respectively. In both cell
types, Panx1 knockdown significantly attenuated TNF-a-induced
ATP release (Fig. 2g; Supplementary Fig. 4f). Finally, we assessed
dye uptake by venous ECs as another output for Panx1 activity.
Incubation of TNF-a-stimulated HUVEC with YO-PRO-1
produced a significant increase in intracellular dye
accumulation in a dose-dependent manner (Supplementary
Fig. 5a,b). This effect was significantly attenuated under
conditions of Panx1 blockade with 10panx1 (Supplementary
Fig. 5c). Moreover, addition of YO-PRO-1 to HUVEC
monolayers 10min or later following TNF-a stimulation
resulted in a significant decrease in dye uptake as compared
with conditions where YO-PRO-1 was present at the onset of
TNF-a stimulation (Supplementary Fig. 5d). These data, along
with the rapid and transient ATP release observed, suggest
that EC Panx1 activation is transient in nature with the
channels closing within 10min of becoming activated by
TNF-a-dependent signalling mechanisms.
To directly investigate the contribution of endothelial Panx1
channels to TNF-a-induced ATP release in the intact venous
circulation, we engineered mice that specifically lack Panx1
expression in ECs. This was accomplished by crossing mice
carrying loxP sites flanking exon 3 of the murine Panx1 gene
(Panx1fl/fl)28 with transgenic mice carrying a tamoxifen-sensitive
Cre recombinase driven by the vascular EC cadherin promoter
(VECadERT2þ ) (Fig. 2h). Because this Cre is basally inactive until
tamoxifen treatment, this allowed the mice to develop normally
and provided the ability to induce deletion of Panx1 specifically in
ECs at the time of our choosing. Following 10 days of tamoxifen
administration, VECadERT2þ /Panx1fl/fl mice displayed a
substantial reduction in Panx1 expression in the endothelium,
as assessed by immunofluorescence microscopy and immune
transmission electron microscopy (iTEM) (Fig. 2i,j). Luminal
perfusion of TNF-a in isolated mesenteric venules from these
mice displayed a marked inhibition of ATP release compared
with littermate controls (that is, injected with the vehicle peanut
oil (PO) only) (Fig. 2k). Taken together, these data suggest a
direct role for Panx1 channels in releasing ATP from venous ECs
in response to TNF-a.
SFK phosphorylate Panx1 in ECs. Next, we aimed to elucidate
the mechanism by which activation of TNFR1 in venous ECs
could translate to Panx1 channel opening. TNFR1 activation has
been reported to induce the activity of a number of intracellular
kinases, including the Src family tyrosine kinases (SFK)29,30. In
addition, endothelial and inflammatory cell SFKs are involved
in increasing EC barrier permeability and increasing the
recruitment, adhesion and transmigration of circulating
neutrophils, monocytes and macrophages to inflamed tissues31.
Recent analysis of Panx1 activity in hippocampal neurons
revealed the involvement of SFKs in NMDA-mediated Panx1
activation32. Therefore, we assessed the potential contribution
of SFKs in TNF-a-induced Panx1 activation and ATP release
from venous ECs. SFK activation can be assessed by
autophosphorylation of a conserved tyrosine residue (Y416),
which stabilizes a substrate-permissive, active-site conformation
in the kinases33. Using a phospho-specific Y416SFK antibody, we
detected a significant increase in Y416 phosphorylation in both
HUVECs (Fig. 3a) and HSaVECs (Supplementary Fig. 4g)
following acute (5min) exposure to recombinant human TNF-a
in vitro, consistent with the rapid induction of ATP release from
these cultured primary cells. This effect was specific to SFK
activation as treatment of both venous cell types with the SFK
inhibitor PP2 reduced Y416 phosphorylation to baseline levels,
while PP3 (the inactive analogue of PP2) had no effect.
Functionally, pharmacological inhibition of SFKs with PP2
significantly blunted TNF-a-induced ATP release from both
HUVEC (Fig. 3b) and HSaVEC (Supplementary Fig. 4h), while
PP3 showed no significant effect. Importantly, examination of
SFK activation downstream of TNF-a signalling in isolated
mesenteric venules revealed a conserved role for SFKs in
promoting ATP release from intact venous endothelium, with
PP2 blunting ATP release (Fig. 3g) and TNF-a increasing SFK
activation (Fig. 3h).
We next sought to determine whether Panx1 channels are
targets for phosphorylation downstream of SFK activation.
Recently, our laboratory defined a region of the Panx1
intracellular loop that is important for receptor-mediated channel
activation in vascular smooth muscle cells. This intracellular loop
region (amino acids 198–200) contains a highly conserved
tyrosine residue (Y198), which may constitute a putative
SFK phosphorylation site34. From these observations, we
developed a new phospho-specific Panx1 antibody against Y198
(pY198Panx1) and a control antibody against the same non-
phosphorylated epitope (Panx1-IL) (Fig. 3c). The pY198Panx1
antibody detects a singular Panx1 species ofB55 kDa by western
blotting (Fig. 3d). Overexpression of c-Src in HUVECs
significantly increased phosphorylation of Panx1 at Y198 as
compared with cells expressing an inhibitor of Src (i-Src)
(Fig. 3e). In addition, this response could be blocked by
inhibition of Src with PP2.
Using this newly developed tool, we addressed Panx1
phosphorylation downstream of TNF-a signalling. Panx1 was
phosphorylated downstream of TNF-a-induced SFK activation in
ECs. Specifically, treatment of HUVEC and HSaVECs with
TNF-a increased phosphorylation at Y198, which could be
blocked by pretreatment with the SFK inhibitor PP2 (Fig. 3f;
Supplementary Fig. 4i). To directly assess the specificity of this
antibody against the phosphorylated form of the channel, we
performed dephosphorylation reactions with alkaline phospha-
tase, which depleted the signal by western blotting. In our ex vivo
vascular preparations, stimulation of primary ECs with TNF-a
also promoted phosphorylation of Panx1 (Fig. 3i). In these
studies, isolated mesenteric venules containing both ECs and
vascular smooth muscle cells were lysed to produce a hetero-
geneous sample. To more accurately discriminate between EC
and vascular smooth muscle cell (VSMC) Panx1 pools, we
performed immunofluorescence microscopy on cross-sections of
mesenteric venules using our pY198Panx1 antibody. Mice
expressing endogenous levels of Panx1 in the vascular wall
(VECadERT2þ /Panx1fl/flþPO) showed a significant increase in
Panx1 phosphorylation following stimulation with TNF-a
(Fig. 3j). Administration of tamoxifen to a subset of mice
abolished this signal, supporting the specificity of pY198Panx1 for
Panx1. These observations provide new evidence for phosphor-
ylation of Panx1 in the venous endothelium in the activation of
these channels during TNF-a signalling.
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Panx1 activation promotes leukocyte adhesion and emigration.
We next tested whether the EC ATP release mediated via this
TNF-a–Panx1 axis may induce leukocyte recruitment to localized
inflammatory foci. We initially used an in vitro leukocyte adhe-
sion assay. In this assay system, activation of HUVEC monolayers
with TNF-a for 30min increased THP-1 monocyte adhesion by
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approximately fourfold (Supplementary Fig. 6a,b). This effect was
significantly reduced by blockade of TNFR1 (WP9QY), Panx1
channels (CBX and 10panx1) and degradation of extracellular
ATP (Apyrase). These in vitro results suggest a potentiating role
for Panx1-dependent ATP release in promoting inflammatory cell
interactions with venous ECs. To more directly determine the
in vivo contribution of Panx1 to acute vascular inflammation, we
used intravital microscopy of the exteriorized mouse cremaster
muscle. Topical application of TNF-a to the cremaster circulation
in C57Bl/6J mice promoted a significant increase in leukocyte
interactions with the post-capillary venular endothelium
(Fig. 4a,b). Specifically, leukocyte adhesion increased B2.5-fold
and emigration increased by B3.5-fold after 120min of TNF-a
stimulation. Genetic deletion of Panx1 specifically in the
endothelium (VECadERT2þ /Panx1fl/fl mice, tamoxifen injected)
potently ablated leukocyte adhesion and emigration compared
with vehicle (PO only)-injected littermates and wild-type
C57Bl/6J control animals. Importantly, the leukocyte rolling
per se was unaffected after endothelial deletion of Panx1, sug-
gesting that the effects of Panx1 activity are required downstream
of the initial rolling stage (Supplementary Fig. 7a). In addition,
venule diameter and wall shear rate did not differ between control
and Panx1-deleted animals (Supplementary Fig. 7a). In addition,
the potent inhibition of adhesion and emigration was not due to
off-target effects of tamoxifen administration per se, as tamoxifen
administration to control C57Bl/6J mice had no effect on these
responses (Supplementary Fig. 7b,c).
Panx1-mediated ATP release upregulates VCAM1. On the basis
of the observation that Panx1 activation primarily regulates
adhesion and transmigration, we sought to examine the effect of
EC Panx1 deletion on the upregulation of VCAM1. VCAM1 is
substantially upregulated during EC activation by cytokines
and functions to bind its complementary ligand a4b1 integrin
(VLA-4) expressed on circulating leukocytes. Binding of VCAM1
to VLA-4 elicits firm adhesion of circulating cells to the
endothelium, allowing downstream emigration into the inflamed
tissue. Recently, several studies have emerged implicating
ATP and purinergic receptor stimulation in VCAM1
upregulation35–37. We performed immunofluorescence microscopy
on TNF-a-stimulated mesenteric venules isolated from our
EC-specific Panx1 knockout (KO) mice to initially assess the
effect on VCAM1 expression. Activation of venules from mice
injected with PO increased total VCAM1 expression in the
endothelium (Fig. 4c). Conversely, deletion of Panx1 by tamoxifen
administration blunted this cytokine-induced VCAM1
upregulation, suggesting a functional role for Panx1 activation in
promoting increased expression of the adhesion molecule (Fig. 4c).
Furthermore, this effect was due to the release of ATP via Panx1,
since VCAM1 upregulation could be rescued in Panx1 KO mice by
stimulating with exogenous ATP (Fig. 4d).
Collectively, these new data identify a previously unrecognized
signalling pathway implicating Panx1 as a positive regulator of
inflammation in the venous endothelium. Specifically, we show
that following activation of TNFR1 on venous ECs, SFKs become
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activated and signal the activation of Panx1 channels. Opening of
the Panx1 pore causes ATP liberation from the cells along a
concentration gradient where it signals extracellularly to promote
leukocyte adhesion to the vascular endothelium and subsequent
emigration into the inflamed tissue (Fig. 4e). Physiologically,
Panx1 channels represent a potential new target for regulating the
purinergic input into inflammatory signalling through TNF-a in
the vasculature, and this may prove useful for future pharmaco-
logical intervention to regulate inflammatory disorders.
Discussion
In the cardiovascular system, ATP and its metabolites function
extracellularly to regulate the vascular inflammatory response,
affecting major aspects of inflammatory signalling in the
endothelium including the presentation of adhesion molecules
and the integrity of the EC barrier function. While multiple lines
of evidence now support a pro-inflammatory role for ATP, the
source and mechanism promoting the cellular release of this
purine nucleotide is not well defined. Here, using multiple
in vitro, ex vivo and in vivo models we provide new evidence
identifying Pannexin 1 channels as major conduits for ATP
release from the venous endothelium during acute inflammatory
stress, with channel activation promoting leukocyte adhesion and
emigration across the vessel wall.
TNF-a and IL-1b are the major cytokines that initially regulate
vascular cell phenotype during acute systemic inflammation.
Increased extracellular concentrations of these signalling mole-
cules is readily observed in a number of inflammatory states,
and recent evidence has emerged linking cytokine signalling by
TNF-a to purinergic pathways in the vasculature3,4. Our analysis
of cytokine-induced ATP release revealed a selective mechanism
by which TNF-a, but not IL-1b, potentiates cellular ATP release
from venous ECs. By these means, EC activation by TNF-a
and subsequent priming for interactions with circulating
inflammatory cells may be favoured by a purinergic
amplification step. This is particularly intriguing when
considering the dichotomous relationship between cell survival
and cell death with respect to TNF-a signalling. This cytokine at
low/acute concentrations favours cell survival pathways and
homeostatic maintenance at the level of inflammatory cell
recruitment through complex I signalling. As such, a purinergic
amplification step may promote non-deletarious signalling in the
absence of chronic TNF-a exposure. In this respect, acute IL-1b
signalling may not require this type of amplification, which is
evidenced by the observed lack of ATP release from ECs exposed
to this cytokine and lack of a synergistic effect when IL-1b and
TNF-a are applied concurrently. This evidence may shed new
light on the complexity of inflammatory signalling in the venous
circulation prompting further analysis of the interplay between
the multiple signalling processes controlling EC activation in the
whole animal during inflammation. Our analysis employed a
range of TNF-a concentrations (0.1–100 ngml 1) to evaluate the
effect on EC ATP release with a significant response observed to
doses at 10 ngml 1 and higher. Depending on the inflammatory
model tested, measurements of endogenous circulating levels
of TNF-a in both humans and animal models have shown
considerable variability; however, these values in general fall in
the pgml 1–ng-ml 1 range. A number of factors likely
contribute to this variation including the absolute systemic
blood volume, activity of TNF-a-processing enzymes and
presence of chelators including soluble TNF receptors. As such,
the absolute concentration of TNF-a in the microenvironment
near the EC surface is likely underestimated by conventional
measurements from serum samples prompting a need for more
sensitive techniques for quantifying cytokine concentrations in
these local environments.
Our study revealed a venous selectivity to TNF-a-induced ATP
release, where ECs of venous origin release ATP following
activation by TNF-a with negligible responses in the arterial
endothelium. In fact, it has long been observed that inflammatory
cell homing to localized tissues occurs almost exclusively in the
post-capillary venous circulation, while these interactions are not
evident in the arterial vasculature until a level of chronic
inflammation is reached38,39. Panx1 channels, therefore, may
provide a regulated mechanism by which physiological homing of
inflammatory cells through the venous endothelium is tightly
regulated.
Here, we have characterized a molecular signalling pathway
involving activation of type-1 TNF receptors, SFK and phosphor-
ylation of Panx1 channels. Recent evidence has identified a novel
role for TNFR1 as a pseudo-receptor tyrosine kinase, achieved
through docking of Src kinase to an intracellular domains of the
receptor29,30. Moreover, the regulation of Panx1 activity by
kinase-driven signalling mechanisms is gaining support.
Specifically, a prominent role for SFK in promoting Panx1
channel activity has been established in neurons during anoxic
depolarizations in ischaemia32. However, to date there has been
no direct evidence for Panx1 phosphorylation. Our analysis of
SFK-dependent Panx1 activation revealed that these channels are
indeed phosphorylated and that this modification may promote
an open-channel state. While the precise mode of Panx1
activation in response to SFK-mediated phosphorylation is still
under investigation, recent reports hypothesize that channel
gating is intimately regulated by interactions between the
C-terminal tail and the channel pore40,41. It is interesting to
speculate that phosphorylation of the Panx1 intracellular loop at
Y198 may impart electrostatic interactions with the C-tail to
sequester this region from the pore and promote an open-channel
conformation. It also currently remains unclear as to whether
Panx1 channels are directly activated by phosphorylation of Y198
or whether additional tyrosine residues are modified contributing
to this effect. In addition to Src, the serine/threonine kinases ERK
and p38MAPK have been reported to rapidly activate in response
to TNF-a stimulation, which may contribute to the regulation
of Panx1 channels in the endothelium42,43. Thus, dynamic
phosphorylation of Panx1 may be evident during vascular
inflammation and be a factor influencing the heterogeneity in
venous versus arterial EC-dependent ATP release.
The kinetics of TNF-a-dependent activation of Panx1 in
venous ECs suggests that the channels operate transiently to
mediate ATP release and downstream purinergic cascades.
Specifically, activation of ECs with TNF-a induced ATP release
and YO-PRO-1 dye uptake within minutes with concurrent SFK
activation and Panx1 phosphorylation. With respect to the
transient nature of Panx1 activity in this response, a number of
regulatory mechanisms may be in place to prevent excessive ATP
release. ATP itself has been reported to negatively regulate
channel activity following accumulation in the extracellular
compartment44. It is suggested that ATP acts allosterically near
the extracellular vestibule of the Panx1 permeation pore to limit
further ATP release. Examination of the kinetics of ATP release
between our cell culture models and perfused vessels revealed a
saturation under static conditions where ATP was allowed to
accumulate in the extracellular milieu surrounding cultured cells.
However, during continuous lumenal perfusion in our isolated
vessel system, ATP continually accumulated in the perfusate,
which may be explained by removal of the purine by flow and
prevention of an ATP block on Panx1 channels. ECs also harbour
an endogenous negative-feedback mechanism to control Panx1
function. Specifically, our lab has reported an inhibitory effect of
the EC-derived bioactive gas nitric oxide (NO) on Panx1 activity
through targeted S-nitrosylation of two conserved cysteine thiols,
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one located in the predicted pore-lining region of the channel and
one in the C-tail15. Targeted S-nitrosylation of these residues
reduces ATP release and Panx1 channel currents in murine ECs.
Activation of EC purinergic receptors by ATP can increase NO
production, which may serve as a possible off switch to prevent
cytosolic ATP depletion and loss of ionic gradients controlled by
ATP-regulated ion transporters. Src is also regulated by
S-nitrosylation with modification reported to increase its kinase
activity45,46. On the basis of these observations, there may be a
dynamic interplay between Src and Panx1 S-nitrosylation during
inflammation, which could regulate the balance between cell
survival pathways and cell death. Of particular interest, the
temporal dynamics of Panx1 and Src post-translational
modification will aid in determining the potential effects of NO
on EC-dependent inflammatory signalling during the acute and
chronic phases. In addition, a prominent role for NO as an
anti-inflammatory mediator has been well established, where
increased NO production in the vasculature reduces leukocyte
rolling, adhesion and emigration47–52. TNF-a can also induce
rapid activation of NADPH oxidase, which may alter the redox
state of cysteine residues in Panx1 and modify NO-dependent
channel regulation42. Future studies will provide useful insight
into the regulation of Panx1 channels by oxidative stress and NO
during inflammatory signalling; however, it is interesting to
speculate that a portion of the anti-inflammatory effects of NO
are due to S-nitrosylation of Panx1 to limit the release of
pro-inflammatory ATP.
Our in vitro and in vivo analyses of leukocyte–EC interactions
in response to the acute inflammatory stimulus TNF-a identified
a major contribution of venous EC Panx1 channels in promoting
adhesion to and extravasation through the vascular wall. Blocking
Panx1 activity pharmacologically in vitro, and molecularly
in vivo, reduced leukocyte adhesion to TNF-a-primed ECs and
abolished emigration of circulating and adherent leukocytes
through post-capillary venules in the exteriorized mouse cre-
master preparation. This effect was specific to the expression of
EC Panx1 channels, since administration of tamoxifen to C57Bl/6
mice had no effect on TNF-a-stimulated adhesion and emigra-
tion (Supplementary Fig. 7b,c) as compared with the potent
ablation in both processes in VECadERT2þ /Panx1fl/fl mice,
which received tamoxifen. No significant differences were seen in
rolling velocity and the absolute number of rolling leukocytes
between animals, indicating that the activity of Panx1 channels
predominantly contributes to the downstream events including
adhesion and emigration. The initial rolling and attachment of
inflammatory cells to the endothelium is controlled primarily by
selectin molecules (P-selectin and E-selectin), while firm adhesion
and extravasation is promoted by the upregulation of VCAM1
and ICAM1. In accordance with this, we observed that deletion of
Panx1 from the endothelium prevented TNF-a-mediated
VCAM1 upregulation implicating Panx1-dependent ATP release
in the latter phase of inflammatory cell homing. This effect could
be rescued by the exogenous application of ATP. These
experiments link previous reports of purinergic signalling
through P2Y receptors in the acute inflammatory cascade with
Panx1-mediated release of ATP from the endothelium. While our
investigation focused on the role of EC Panx1 channels and the
role of released ATP on EC phenotype, leukocytes also use
purinergic signalling for activation during inflammation53–55. It is
now evident that neutrophils release ATP in response to
activation by danger signals. In particular, activation of
neutrophils with fMLP promotes ATP release in part via Panx1
channels, which signals in an autocrine fashion to activate P2Y2
receptors and promote chemotaxis56. Neutrophils also express
TNF receptors; however, whether activation of these receptors
induces Panx1 activation or ATP released from EC Panx1
channels contributes to neutrophil chemotaxis has not been
investigated. Nonetheless, it is possible that the reduced
interactions observed between endogenous leukocytes and the
venous endothelium in EC Panx1 KO mice may reflect
diminished purinergic signalling in both ECs and the
inflammatory cells. Taken together, the results presented in this
study highlight a novel role for EC Panx1 channels in the
regulation of acute vascular inflammation, poising Panx1 as a
linking factor between TNF-a signalling and purinergic control of
inflammatory cell interactions with the blood vessel wall.
Methods
Cell culture. Primary HUVECs were purchased from Cell Applications (200K-05).
Primary HSaVECs and HAoECs were from PromoCell (C-12231 and C-12271,
respectively) and HCoAECs were purchased from Lonza (CC-2585). All ECs were
maintained under standard cell culture conditions in endothelial growth medium
(EGM-2MV) from Lonza. For siRNA knockdown of Panx1 and Cx43, HUVEC and
HSaVECs were plated in six-well (expression) or 24-well plates (ATP release) and
grown to 70–80% confluence. Non-targeting siRNAs (Life Technologies silencer
select negative control 1, 4390843) or siRNAs targeting the human PANX1 gene
(Life Technologies Panx1 silencer select 4392420-s24427; 50-GUUUGUGGGAG
GUAUCUGAtt-30) or Cx43 (Life Technologies GJA1 silencer select 4392420-s5758;
50-GGCUAAUUACAGUGCAGAAtt-30) were transfected into ECs using
Lipofectamine RNAiMAX reagent, and knockdown was assessed via western
blotting following a 72-h incubation.
Mice. All mice were male, 10–14 weeks of age, on a C57Bl/6J genetic background,
and were cared for under the provisions of the University of Virginia Animal Care
and Use Committee and the LSU Health Sciences Center-Shreveport Animal Care
and Use Committee and followed the National Institute of Health guidelines for the
care and use of laboratory animals. The inducible, EC-specific Panx1 KO mice
(VECadERT2þ /Panx1fl/fl) were generated by crossing VECadERT2þ /Panx1WT/WT
mice (a kind gift from Dr Ralf Adams, Max Plank Institute, Germany) with
VECadERT2 /Panx1fl/fl mice28. To selectively induce Panx1 deletion in the
vascular endothelium, VECadERT2þ /Panx1fl/fl mice received intraperitoneal
injections of Tamoxifen (1mg in 0.1ml PO) for 10 consecutive days. A subset of
VECadERT2þ /Panx1fl/fl mice were injected with PO (the vehicle for tamoxifen)
and served as littermate controls.
ATP release assays. In vitro. Human arterial and venous ECs were seeded in
24-well plates pre-coated with 0.2% gelatin and grown to confluency. On the day of
the experiment, the media was removed from each well and cells were carefully
washed twice with warm serum-free basal EC medium supplemented with 1% BSA.
Cells were then incubated in 300 ml of fresh basal EC medium supplemented with
1% BSA for 30min at 37 C to allow degradation of extracellular ATP released due
to mechanical stimulation during washes. Endogenous ecto-nucleotidases were
inhibited by incubating EC monolayers with 300 mM ARL 67156 (Tocris) for
30min at 37 C. Cells were then stimulated with recombinant human TNF-a (R&D
Systems). For dose–response experiments, ECs were incubated with 0.1, 1, 5, 10, 50
or 100 ngml 1 recombinant TNF-a for 30min at 37 C. For time-course experi-
ments, ECs were stimulated with 10 ngml 1 recombinant TNF-a for different
time points up to 1 h. In experiments where pharmacological inhibitors were
employed, ECs were incubated with antagonists in parallel with ARL 67156 for
30min. To inhibit TNFR1, ECs were incubated with the peptide antagonist of the
receptor WP9QY (10 mM; Anaspec). Vesicular ATP release was inhibited with BFA
(5 mgml 1; Sigma) and CALHM1 channels were pharmacologically blocked with
ruthenium red (20 mM; Sigma). Cx hemichannels were inhibited with lanthanum
(La3þ ; 100 mM; Sigma) and Panx1 channels were blocked with CBX (50 mM;
Sigma) and the inhibitory peptide 10panx1 (200 mM; Genscript). To assess the role
of SFK, cells were incubated with the SFK inhibitor PP2 (10 mM; Tocris) or its
inactive analogue PP3 (10mM; Tocris). The role of caspase activation was assessed
by inhibition with the pan-caspase blocker Q-VD-OPh (100 mM; Sigma). Following
stimulation with TNF-a or vehicle, 150ml of the cell supernatant was collected and
immediately placed into pre-chilled 1.5ml Eppendorf tubes on ice. All samples
were centrifuged at 10,000g for 5min and 50 ml of each sample was transferred
to a white, opaque 96-well plate. Using a FluoStar Omega luminometer, 50 ml of
luciferin:luciferase reagent (ATP bioluminescence assay kit HSII; Roche) was
injected into each well and luminescence was recorded following a 5-s orbital mix.
ATP concentration in each sample was calculated from a standard curve for all
experiments. Data are presented as a % change in ATP release from baseline
(that is, unstimulated cells) and expressed as mean±s.e.m. (n¼ 5 independent
experiments with triplicate measurements).
Ex vivo. For isolated blood vessel experiments, seconed-order venules or arterioles
were dissected from the mouse mesentery circulation and cannulated on glass
micropipettes to access the vessel lumen. Following cannulation, vessels were
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perfused lumenally with a MOPS-buffered physiological salt solution (NaCl
145mM, KCl 4.7mM, CaCl2 2mM, MgSO4 1.17mM, NaH2PO4 1.2mM, glucose
5mM, pyruvate 2mM, EDTA 0.02mM and MOPS 2mM) to remove red blood
cells and equilibrated at 37 C for 20min. Vessels were then perfused with MOPS
PSS containing 300mM ARL 67156 þ / pharmacological inhibitors and
incubated for an additional 20min prior to perfusion with MOPS PSS containing
recombinant murine TNF-a (R&D Systems). Aliquots of the lumenal perfusate
were collected every 5min for a 25-min period, and the ATP concentration was
quantified by bioluminescence as described above. Data are expressed as
mean±s.e.m. (n¼ 4 independent experiments).
LDH release assays. Isolated mesenteric venules were cannulated and perfused
with recombinant mouse TNF-a for 20min followed by lysis buffer. Perfusate
samples were collected as described above and LDH activity was assayed with the
Cytotoxicity Detection Kit Plus (Roche) according to the manufacturer’s protocol
as an output for cell death. Data are expressed as mean±s.e.m. (n¼ 3 independent
experiments).
YO-PRO-1 dye uptake assays. HUVECs were cultured on poly-L-lysine-coated
coverslips and grown to confluence in EGM. Cells were washed three times
with 1 PBS and incubated in fresh EGM for 30min prior to stimulation.
To stimulate YO-PRO-1 dye uptake, YO-PRO-1 (1 mM) was added to the media
and EC monolayers were treated with TNF-a at a range of concentrations
(0.1–100 ngml 1) for 30min. At the end of the stimulation, cells were washed 3
with 1 PBS and immediately fixed in 4% paraformaldehyde (PFA). Coverslips
were then mounted on microscope slides with DAPI Prolong Gold mounting agent
and visualized on an Olympus IX81 laser scanning confocal microscope. Dye
uptake was quantified as the intensity of YO-PRO-1 fluorescence over time
using ImageJ software. For time-course analysis, YO-PRO-1 was added to the
culture media at various time points after TNF-a stimulation and incubated to
the 30-min time point. Data are expressed as mean±s.e.m. (n¼ 3 independent
experiments).
Connexin hemichannel depletion/cell surface biotinylation. Cell surface
biotinylation was performed as described previously15. To deplete Cx43
hemichannels from the EC plasma membrane, venous and arterial ECs were grown
to confluency in six-well plates (western blotting) or 24-well plates (ATP release)
and treated with the vesicular exocytosis inhibitor BFA (5 mgml 1) for 5 h at
37 C. Cells were washed once with cold 1 PBS and incubated with cold DMEM
(without FBS) and 50mM CBX at 4 C for 30min. CBX was added to prevent biotin
from passing through Panx1 channels, which may label intracellular proteins. Cells
were washed with PBS and incubated at 4 C for 1 h in cold PBS (1.5ml per dish)
containing EZ-link-sulfo-NHS-LC-biotin (1mgml 1) and CBX (50mM). The cells
were washed again with PBS and lysed in PBS-T (PBSþ 0.5–1% Triton-X 100)
containing protease inhibitors. Total protein was quantified using the bicinchoninic
(BCA) assay and equal amounts of protein were incubated with streptavidin-
agarose beads for 2 h at 4 C to pull down biotinylated (cell surface) proteins. Beads
were then washed five times with 1 PBS-T, pelleted by centrifugation and
proteins eluted by incubation with 5 sample buffer. Eluted proteins were
subjected to SDS–polyacrylamide gel electrophoresis and western blotting for
detection of Cx43 and Panx1.
Immunofluorescence microscopy. Male VECadERT2þ /Panx1fl/fl mice
(tamoxifen or PO injected) were euthanized by CO2 asphyxiation and subsequent
cervical dislocation. Prior to tissue harvesting, fixation was performed by perfusing
room temperature 4% PFA made in PBS through the heart. The mesentery was
immediately excised and second-order venules were dissected free of surrounding
fat and connective tissue and placed in 4% PFA for 30min before transfer to 70%
ethanol for paraffin embedding. Paraffin sections (4–5 mm in thickness) were
deparaffinized and processed for immunocytochemistry as previously described10.
For validation of Panx1 KO in the endothelium, vessel sections were processed for
conventional immunolabelling and incubated overnight at 4 C with a primary
antibody directed against the murine Panx1 C-tail26. To analyse VCAM1
expression, a polyclonal antibody to murine VCAM1 was used (Abcam; 1:500).
Immuno-transmission electron microscopy (iTEM). This was performed as
previously described, using an extracellular loop Panx1 antibody11. Gold beads
were pseudo-coloured pink for visualization.
Western blotting for Src-family kinase/Panx1 phosphorylation. Following
stimulation with TNF-a (in vitro: 10 ngml 1; ex vivo: 50 ngml 1), confluent
EC monolayers or isolated mesenteric venules were homogenized in ice-cold
Triton extraction buffer (50mM Tris-HCL, 150mM NaCl, 5mM EDTA, 1%
deoxycholate, 1% NP-40 and 1% Triton-X100 in PBS and pH adjusted to 7.4)
containing protease and phosphatase inhibitors. Cell/tissue lysates were incubated
with rotation at 4 C for 20min to solubilize proteins, followed by centrifugation
for 5min at 13,000g to pellet cell debris. Protein concentration was quantified
using the BCA method. In all, 15–20 mg of total protein was subjected to SDS
gel electrophoresis using 4–12% Bis-Tris gels (Invitrogen) and transferred to
nitrocellulose membranes for immunoblotting. Membranes were blocked for 1 h at
room temperature with LiCOR blocking solution, then incubated overnight at
4 C with primary antibodies against pY416SFKs (BD Biosciences; 1:1,000),
pY198Panx1 (Alpha Diagnostic Intl (ADI); 1:1,000) and GAPDH (Sigma; 1:10,000)
or an antibody against the intracellular loop of Panx1 (Panx1-IL) (ADI; 1:1,000)
(normalization controls). Membranes were then washed and incubated with
LiCOR secondary antibodies (1:10,000) and visualized and quantified using LiCOR
Odyssey. To inhibit SFK activity, EC monolayers were incubated with the SFK
inhibitor PP2 (Tocris; 10 mM). The inactive analogue PP3 (Tocris; 10 mM) was used
as a negative control for PP2. To show specificity for the phosphorylated form of
SFKs and Panx1, cell lysates were incubated with alkaline phosphatase for 1 h at
37 C. Western blot images have been cropped for presentation. Uncropped
western blots can be found in Supplementary Figs 8 and 9. Data are expressed as
mean±s.e.m. (n¼ 3 independent experiments).
Static adhesion assay. HUVECs were seeded on gelatin-coated glass coverslips in
six-well plates and grown to confluence. On the day of the experiment, cells were
washed 2 with 1 PBS and incubated for 30min in basal EGM supplemented
with 1% BSA in the presence or absence of pharmacological inhibitors. During this
incubation period, human THP-1 monocytes were loaded with Calcein-AM
(Invitrogen; 5 mgml 1) for 30min at 37 C. Cells were then pelleted by brief
centrifugation and excess calcein was removed by washing THP-1 cells three times
in 1 PBS. Next, HUVECs were stimulated with TNF-a (10 ngml 1) for 30min.
Following EC activation, calcein-loaded THP-1 monocytes were added to EC
monolayers and incubated for 20min at 37 C to allow THP-1 to contact ECs.
Monolayers were then washed 3 with 1 PBS and fixed in ice-cold 4% PFA.
Following fixation, coverslips were removed from the six-well plates and mounted
on glass microscope slides with Prolong Gold anti-fade mountant with DAPI (Life
Technologies). Fluorescent micrographs were obtained at  10 magnification and
the number of adherent THP-1 monocytes/ECs was quantified in five randomized
regions per slide. Data are expressed as mean±s.e.m. (n¼ 3 independent
experiments).
Intravital microscopy for leukocyte adhesion and emigration. Mice were pre-
pared for intravital microscopy of the cremaster muscle as described previously57.
Briefly, mice were anaesthetized with ketamine hydrochloride (150mg kg 1) and
xylazine (7.5mg kg 1), intraperitoneally. The cremaster was isolated, laid over a
viewing pedestal, superfused with bicarbonate-buffered saline. After 30min
equilibration, a venule with a wall shear rate of Z500 s 1, diameter between 20
and 40mm and the least number of adherent and emigrated leukocytes was chosen
for further study. A 1-min baseline recording was made, after which superfusion
was stopped, and 50 ml TNF-a (1.7 ngml 1 in 0.1% BSA) or vehicle control was
added under a saran wrap cover every 30min. One-minute recordings were made
just prior to each addition, for 3 h. The TNF-a was initially reconstituted in PBS at
3.4 ngml 1 and 150-ml aliquots were frozen. An aliquot was mixed 1:1 with BBS
containing 0.2% BSA at the time of the experiment. Leukocyte adhesion and
emigration were determined by off-line analysis. Leukocytes were considered
adherent if they stopped for at least 30 s (expressed as number of cells per mm2
vessel wall), and emigrated leukocytes were leukocytes identified in the interstitium
(expressed as number of cells per mm2 tissue). Data are expressed as mean±s.e.m.
(n¼ 6–7 independent animals per group).
Statistics. All statistics were performed using GraphPad Prizm software. For
multiple comparisons, statistics were performed using a one-way or two-way
analysis of variance followed by pairwise analysis. A Student’s t-test was used for
individual comparisons if normally distributed.
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